French (CAC) Biotech Industry Analysis

Industry Valuation and Performance

Has the French Biotech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 07 Aug 2026	€12.1b	€506.2m	-€885,573,228.86	16.7x	-13.7x	23.9x
Sun, 05 Jul 2026	€14.4b	€507.6m	-€879,744,569.28	17.8x	-16.4x	28.4x
Tue, 02 Jun 2026	€11.9b	€493.6m	-€853,667,330.14	18.7x	-14x	24.2x
Thu, 30 Apr 2026	€10.2b	€496.1m	-€816,335,900.42	16x	-12.5x	20.5x
Sat, 28 Mar 2026	€10.2b	€547.8m	-€842,291,467.24	12.5x	-12.1x	18.6x
Mon, 23 Feb 2026	€12.2b	€559.5m	-€763,239,517.03	13.9x	-16x	21.9x
Wed, 21 Jan 2026	€11.4b	€559.9m	-€763,907,103.04	13.6x	-14.9x	20.3x
Fri, 19 Dec 2025	€10.3b	€641.4m	-€693,880,345.06	10.3x	-14.8x	16x
Sun, 16 Nov 2025	€2.4b	€653.3m	-€395,757,741.83	10.2x	-6.1x	3.7x
Tue, 14 Oct 2025	€2.6b	€643.9m	-€435,903,291.35	15.8x	-6x	4x
Thu, 11 Sep 2025	€2.4b	€681.7m	-€467,694,449.60	13.9x	-5.1x	3.5x
Sat, 09 Aug 2025	€2.3b	€663.8m	-€459,364,106.83	15.7x	-5.1x	3.5x
Mon, 07 Jul 2025	€2.0b	€665.3m	-€492,593,507.40	16.1x	-4x	2.9x
Wed, 04 Jun 2025	€2.1b	€668.0m	-€498,989,528.07	15.9x	-4.1x	3.1x
Fri, 02 May 2025	€2.5b	€646.2m	-€574,914,187.32	38.6x	-4.3x	3.8x
Sun, 30 Mar 2025	€2.3b	€658.7m	-€557,189,433.28	15.2x	-4.2x	3.6x
Tue, 25 Feb 2025	€2.7b	€649.9m	-€525,737,224.50	17.1x	-5x	4.1x
Thu, 23 Jan 2025	€2.3b	€649.7m	-€525,722,071.57	14.5x	-4.4x	3.6x
Sat, 21 Dec 2024	€2.3b	€654.7m	-€549,763,446.36	17.6x	-4.1x	3.5x
Mon, 18 Nov 2024	€2.5b	€654.6m	-€545,152,944.52	18.1x	-4.6x	3.9x
Wed, 16 Oct 2024	€2.7b	€627.6m	-€512,068,697.21	19.5x	-5.3x	4.3x
Fri, 13 Sep 2024	€3.0b	€525.1m	-€610,002,375.53	36.3x	-4.9x	5.7x
Sun, 11 Aug 2024	€3.0b	€517.2m	-€592,041,744.40	37x	-5x	5.7x
Tue, 09 Jul 2024	€2.9b	€511.8m	-€567,006,124.68	26.9x	-5.2x	5.7x
Thu, 06 Jun 2024	€3.4b	€509.6m	-€564,051,021.88	27.9x	-6x	6.6x
Sat, 04 May 2024	€3.2b	€503.5m	-€661,036,205.47	27.4x	-4.8x	6.4x
Mon, 01 Apr 2024	€3.2b	€501.1m	-€565,863,629.05	21.8x	-5.6x	6.3x
Wed, 28 Feb 2024	€3.2b	€558.7m	-€673,845,757.17	21.8x	-4.7x	5.6x
Fri, 26 Jan 2024	€3.1b	€594.6m	-€685,069,862.00	21.8x	-4.5x	5.2x
Sun, 24 Dec 2023	€3.2b	€594.1m	-€682,066,929.00	23x	-4.7x	5.4x
Tue, 21 Nov 2023	€3.4b	€594.1m	-€682,775,373.00	21.7x	-4.9x	5.7x
Thu, 19 Oct 2023	€3.3b	€806.5m	-€616,633,716.00	20.4x	-5.3x	4.1x
Sat, 16 Sep 2023	€3.9b	€818.2m	-€729,216,139.00	23.8x	-5.3x	4.7x
Mon, 14 Aug 2023	€3.7b	€817.7m	-€724,994,707.00	24.3x	-5.2x	4.6x

Current Industry PE

Investors are optimistic on the French Biotechs industry, and appear confident in long term growth rates.

The 3-year average PS ratio of 8.0x is lower than the industry's current PS ratio of 23.8x.

Past Earnings Growth

The earnings for companies in the Biotechs industry have deteriorated over the last three years.
Revenues have also declined 15% per year.
This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Trends

Which industries have driven the changes within the French Healthcare industry?


FR Market	2.21%
Healthcare	2.77%
Biotech	0.87%
Biotech	0.87%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
ABVX ABIVAX Société Anonyme	€110.20	1.6% +€146.5m	81.8%	PS1930.8x
IVA Inventiva	€4.03	2.5% +€23.6m	40.2%	PS140.7x
DBV DBV Technologies	€2.43	2.0% +€14.2m	41.0%	PS164.8x
VLA Valneva	€2.22	2.6% +€10.6m	-38.1%	PS2.7x
ALSEN Sensorion	€0.28	2.7% +€3.9m	-12.2%	PS25.2x

Valerio Therapeutics Enters into Binding Term-Sheet with Abivax for Exclusive Global Research and Development Collaboration and Provides Pipeline Update

Valerio Therapeutics entered into a binding term-sheet with Abivax, setting out the principal terms of an exclusive worldwide research and development collaboration. The final terms remain subject to the signing of the definitive co-ownership and license agreement. In connection with this collaboration, Valerio Therapeutics and Abivax will work together to identify, design and evaluate next-generation therapeutic candidates for immune-mediated inflammatory diseases, leveraging Abivax’s expertise in this area together with Valerio Therapeutics' targeted technology platforms. The collaboration will include the generation, manufacturing and preclinical evaluation of research candidates. The candidates will be evaluated for their therapeutic potential and may be further developed by Abivax. Under the terms of the binding term-sheet, Valerio Therapeutics will receive an upfront payment up to approximately EUR 2.4 million and would be eligible to receive development and commercial milestone payments, as well as royalties on net sales and sublicensing revenues, subject to the execution of the definitive co-ownership and license agreement and the achievement of specified milestones and other terms. For Valerio Therapeutics, the execution of this binding term-sheet represents an important milestone in the evolution of the Company as a precision RNA therapeutics developer with a growing pipeline. The partnership with Abivax will provide non-dilutive funding to support pipeline advancement, will supplement the existing potential for future milestone and royalty revenues and will reinforce the attractiveness of Valerio Therapeutics’ technology platform to biotech and pharmaceutical partners. This transaction is aligned with Valerio Therapeutics’ strategy of advancing a focused portfolio of wholly owned therapeutic programs while complementing these efforts through partnerships and licensing transactions that leverage its platform capabilities and create additional value creation opportunities. Valerio Therapeutics will provide further updates in due course, including upon signature of the definitive co-ownership and license agreement, in accordance with its obligations under the binding term-sheet and applicable regulatory obligations. Valerio Therapeutics is advancing a pipeline of precision RNA therapeutics focused on diseases where targeted delivery to specific immune cells enables differentiated treatment approaches. The Company’s lead programs have been selected based on a combination of strong disease biology, clear unmet medical need and the ability to leverage Valerio Therapeutics’ proprietary V-Body platform to direct RNA-based payloads to disease-relevant tissue. The proprietary pipeline currently includes the lead program VTX-001 in ankylosing spondylitis, VTX-002 in IgG4-related disease and VTX-003 in oncology. VTX-001 and VTX-002 are next-generation in vivo CAR-T approaches in the immunity & inflammation field and are designed to selectively deplete pathogenic immune-cell populations, while VTX-003 uses a V-Body–oligonucleotide conjugate approach to deliver siRNA to reactivate exhausted T cells in oncology. Valerio Therapeutics’ platform is designed to accelerate discovery and development by enabling rapid generation of tailored V-Bodies, which can be combined with RNA payloads and next-generation lipid nanoparticle technologies across multiple therapeutic modalities. The Company's strategy and pipeline reflect a milestone-driven approach to value inflection, with the ambition to nominate up to two development candidates within 12 to 18 months and to progress at least one program into first-in-human clinical studies within 18 to 24 months.

French (CAC) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Price target decreased by 8.3% to €1.14

Cellectis S.A. to Report Q2, 2026 Results on Aug 06, 2026

Abivax Announces Positive Pre-NDA Interaction With FDA For Obefazimod

Pediatric Peanut Allergy Treatment Pipeline Will Support A Long-Term Bullish Thesis

Eurobio Scientific Société anonyme to Report First Half, 2026 Results on Sep 24, 2026

Investor sentiment deteriorates as stock falls 28%

New minor risk - Profitability

NANO: CONVERGE Data Will Drive Bullish Repricing Despite Execution Risks

Innate Pharma Completes Enrollment in Dose Escalation of Phase 1 Study of IPH4502

Consensus revenue estimates increase by 24%

Valerio Therapeutics Enters into Binding Term-Sheet with Abivax for Exclusive Global Research and Development Collaboration and Provides Pipeline Update

Forecast to breakeven in 2028

VLA: Travel Vaccine Headwinds Will Set Up Future Repricing Potential

TNG: Early Cancer Vaccine Data Will Drive Future Repricing

GENFIT Reports Positive Phase 1B Data for GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

Biophytis S.A. announced delayed 20-F filing